Betaine HCl (Betaine Hydrochloride)

Betaine HCl is one of the most misunderstood supplements on the market, and the honest review has to start by separating it from a different molecule with the same prefix. Betaine HCl is betaine bonded to hydrochloric acid, taken as an oral acidifier to temporarily lower gastric pH in people with low stomach acid. TMG, trimethylglycine, and betaine anhydrous are the same molecule sold under different names and are used as a methyl donor for homocysteine lowering and exercise performance. The two share the betaine moiety but have completely different use cases, different evidence bases, and different safety profiles. If you bought betaine HCl expecting methylation support, or bought TMG expecting digestive support, you got the wrong product. This confusion is rampant in consumer reviews, on retailer pages, and in functional medicine messaging, and it is the single most important thing to get right before reading further.

The strongest piece of evidence for betaine HCl is Yago 2013, a small open-label study in six healthy volunteers given 20mg rabeprazole twice daily for four days to pharmacologically suppress their stomach acid, then dosed with 1500mg betaine HCl. Gastric pH dropped from about 5.2 to 0.6 within 30 minutes, reaching below pH 3 in roughly 6 minutes. The acidification persisted for approximately 73-77 minutes. This is the trial that drug-formulation researchers cite, the trial that integrative-medicine reviews cite, and the trial that essentially every product page references. It establishes one fact clearly: in induced hypochlorhydria, a 1500mg dose of betaine HCl does lower gastric pH, and the effect is rapid and temporary. What it does not establish is that betaine HCl improves any clinical outcome - it was not designed to. The original purpose was to support the absorption of pH-dependent drugs like dasatinib in patients on proton pump inhibitors.

The next-tier evidence is Guilliams and Drake 2020, a review article in the integrative medicine literature that examined betaine HCl supplementation in functional hypochlorhydria and concluded that the mechanism is plausible but the clinical evidence is thin. Beyond these two papers, there are no large randomized controlled trials demonstrating that betaine HCl improves digestive symptoms, nutrient absorption, or any patient-reported outcome at the population level. The supplement-industry case for betaine HCl rests almost entirely on mechanism plus the Yago 2013 pharmacokinetic demonstration.

The self-diagnosis problem is the second reason this profile carries so many caveats. Symptom checklists used to identify low stomach acid - bloating, gas, post-meal fullness, indigestion, belching, feeling like food sits in the stomach - overlap nearly perfectly with the symptoms of high stomach acid conditions (GERD, gastritis, peptic ulcer), with H pylori infection, with SIBO, with delayed gastric emptying, and with functional dyspepsia. There is no validated symptom-based test for hypochlorhydria. The Heidelberg gastric pH capsule test is the historical gold standard but is rarely available clinically. The popular at-home "betaine HCl challenge" (escalate dose until you feel burning, then back off) has no validation literature behind it and treats the absence of a burning sensation as diagnostic - a logic that doesn't survive contact with the fact that high-acid conditions can also produce no burning at low betaine HCl doses. People who self-treat presumed low stomach acid with betaine HCl when they actually have gastritis, GERD, or active ulcer disease can experience meaningful symptom worsening. The 2026 Hurwitz JAMA study (n=248 community-dwelling adults 65+) found that nearly 90 percent of older adults retained the ability to acidify gastric contents even in the basal unstimulated state - which directly contradicts the longstanding folk-medicine claim that hypochlorhydria becomes near-universal with age.

The third issue is that hydrochloric acid is one of several factors required for protein digestion and micronutrient absorption, but it is not always the rate-limiting one. Pepsinogen activation, intestinal motility, pancreatic enzyme output, bile flow, and intestinal mucosal health all contribute. Improving one of these in isolation - which is what betaine HCl does - may not translate into a felt improvement if the bottleneck is elsewhere. The strongest theoretical use case is in patients with confirmed achlorhydria (often from autoimmune atrophic gastritis, long-term PPI use, post-bariatric surgery anatomy, or H pylori-associated atrophic gastritis) who are demonstrably malabsorbing protein, B12, iron, or calcium. In those patients, addressing the underlying cause is medicine; betaine HCl is at best an adjunct under physician supervision.

Practical bottom line: betaine HCl is a niche supplement with a narrow legitimate use case. It can briefly lower gastric pH in people who actually have low stomach acid - a population that is smaller and harder to identify than supplement marketing implies. It is contraindicated in active GI disease, in PPI/H2 blocker users, and during pregnancy. It does not treat reflux, gastritis, ulcers, H pylori, IBS, or generic indigestion, despite frequent off-label marketing to all of those conditions. Anyone considering it should first rule out higher-likelihood causes of their symptoms with a clinician, ideally with H pylori testing and a basic GI workup, before assuming the problem is too little acid rather than too much or something else entirely.